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Abstract In many biomedical applications, the perfor-
mance of biomaterials depends largely on their degradation
behavior. For instance, in drug delivery applications, the
polymeric carrier should degrade under physiological
conditions slowly releasing the encapsulated drug. The aim
of this work was, therefore, to develop an enzymatic-
mediated degradation carrier system for the delivery of
differentiation agents to be used in bone tissue engineering
applications. For that, a polymeric blend of starch with
polycaprolactone (SPCL) was used to produce a micro-
particle carrier for the controlled release of dexamethasone
(DEX). In order to investigate the effect of enzymes on the
degradation behavior of the developed system and release
profile of the encapsulated osteogenic agent (DEX), the
microparticles were incubated in phosphate buffer solution
in the presence of a-amylase and/or lipase enzymes (at
physiological concentrations), at 37C for different periods
of time. The degradation was followed by gravimetric
measurements, scanning electron microscopy (SEM) and
Fourier transformed infrared (FTIR) spectroscopy and the
release of DEX was monitored by high performance liquid
chromatography (HPLC). The developed microparticles
were shown to be susceptible to enzymatic degradation, as
observed by an increase in weight loss and porosity with
degradation time when compared with control samples
(incubation in buffer only). For longer degradation times,
the diameter of the microparticles decreased significantly
and a highly porous matrix was obtained. The in vitro
release studies showed a sustained release pattern with
48% of the encapsulated drug being released for a period of
30 days. As the degradation proceeds, it is expected that
the remaining encapsulated drug will be completely
released as a consequence of an increasingly permeable
matrix and faster diffusion of the drug. Cytocompatibility
results indicated the possibility of the developed micro-
particles to be used as biomaterial due to their reduced
cytotoxic effects.
1 Introduction
Development of materials in the particulate form has been a
subject of great interest for several decades. In fact, nowa-
days polymeric microparticles have been used in several
applications, including chemical, biological and medical
uses [1–4], and more recently in Tissue Engineering research
[1, 5–7]. Since the early 80s, the possibility of incorporating
different drugs and bioactive agents into small polymeric
vehicles, was predicted as a promising approach for the
administration of those agents [1, 8–10]. More recently, the
use of biodegradable polymers to design controlled drug
delivery carriers, having the additional advantage of mini-
mizing the need for device removal after the release of the
bioactive agent, has been reported [9].
The fact that the degradation process affects, and ultimately
controls the rate of drug release from biodegradable carriers,
controlling the degradation rate of polymeric materials has
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been one of the critical issues in general biomaterials research
[11]. A potential disadvantage of using biodegradable poly-
mers in biomedical applications is the eventual toxicity of the
degradation products, which are aimed at being non-toxic
leachables and easy metabolized molecules [12].
Biodegradable starch-based polymers have been proposed
for several biomedical applications such as drug delivery
systems [13, 14], bone cements [15] and bone tissue engi-
neering scaffolding [16, 17], due to their great processing
versatility [17] and to their promising properties regarding
biodegradability [18] and biocompatibility [12, 19].
The aim of this study was to develop an enzymatic-
mediated degradation carrier system, based on a blend of
starch with poly-e-caprolactone in microparticulate form,
for the controlled release of differentiation agents for bone
tissue engineering applications. For this purpose, the deg-
radation behavior of the developed system was investigated
in presence of relevant enzymes and the release of dexa-
methasone was studied under these conditions. The
cytotoxicity of the developed system was also assessed by
culturing osteoblast-like cells in extracts of the materials
after increasing incubation periods in cell culture medium.
2 Experimental
2.1 Materials
The studied material was a polymeric blend of corn starch
with poly-e-caprolactone (SPCL, 30–70 wt.%). The mate-
rial was originally in a granular form. More details on this
material can be found elsewhere [20]. Dexamethasone
(DEX, HPLC grade, C98%, Sigma) was used as a bioactive
molecule for the encapsulation studies. Solvents used in
HPLC analysis were HPLC grade. Other chemicals were of
reagent grade and used as received.
The enzymes selected for this study were a-amylase (EC
3.2.1.1) from Aspergillus oryzae and lipase (EC 3.1.1.3)
from Aspergillus oryzae, both purchased from Sigma–
Aldrich Chemical Co. (St. Louis, USA).
2.2 Methods
2.2.1 Preparation of starch-poly-e-caprolactone
(SPCL) microparticles
The SPCL microparticles were prepared as previously
described [21]. Briefly, SPCL was dissolved in methylene
chloride under vigorous stirring. This solution was dropped
into a 200 ml PVA solution, and emulsified under agitation
(600 rpm) for 4 h. The microparticles were then collected
by filtration, washed with distilled water and dried under
vacuum. For encapsulation of DEX, the drug was directly
added to the polymeric solution at 15% (wt.%, relatively to
polymer weight).
2.2.2 In vitro enzymatic degradation study
The enzymatic degradation of the developed carrier system
was investigated by incubating the microparticles in a ratio
1:10 with phosphate buffered saline solution (PBS, 0.01 M,
pH 7.4) containing a-amylase (150.5 U/l) and/or lipase
(102 U/l), at 37C and 60 rpm up to 12 weeks. To avoid
microbial growth, sodium azide (0.02%) was added to the
degradation solution. As a control, the samples were also
incubated in PBS solution without enzymes. At the end of
the pre-selected degradation times, the supernatants were
removed and stored at -80C until further analysis. The
microparticles were then thoroughly washed with distilled
water and allowed to dry at room temperature until con-
stant weight. The final weight of the samples was used for
the calculation of the weight loss [22]. The supernatant
solutions were used to determine the concentration of
reducing sugars released into the solution as a result of
starch degradation (hydrolysis of glycosidic linkages in
starch molecule with the consequent release of soluble
oligosaccharides). The amount of reducing sugars was
estimated by the dinitrosalicylic acid (DNS) method [23].
Experiments were performed in triplicate for all the
conditions.
2.2.3 Physical and chemical characterization
The changes on the surface morphology of the micropar-
ticles after degradation were analyzed by Scanning electron
microscopy (SEM, Leica Cambridge S-360 model (Cam-
bridge, UK)). The samples were fixed to the support using
a carbon tape and gold sputter-coated (Fisons Instruments,
Sputter Coater SC502, UK) prior to observation.
To assess eventual changes in the chemical composition
caused by the degradation process, the microparticles were
analyzed by Infrared spectroscopy in transmission mode
(FTIR-IRPrestige-21 FRIT-8400S, Shimadzu, Japan). Pre-
weighed microparticles (1 mg) were mixed with KBr
(40 mg) and then formed into a disc in a press. Transmission
spectra were recorded using at least 32 scans with 4 cm-1
resolution, in the spectral range of 4,000–600 cm-1.
2.2.4 In vitro release of DEX from SPCL microparticles
The release of DEX encapsulated in the SPCL micropar-
ticles was assessed in PBS only and in PBS containing
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a-amylase and lipase enzymes in order to investigate the
effect of enzymatic degradation on the release kinetics of
DEX. For that, the microparticles were suspended in the
release solution (2.5 mg/ml). Samples were maintained at
37C and 50 rpm up to 4 weeks. At pre-determined time
periods, 1 ml aliquots were taken from the supernatant and
replaced with the same volume of fresh medium solution.
All the release experiments were carried out in triplicate.
Released DEX was quantified by reverse phase high-
performance liquid chromatography (RP-HPLC). Before
chromatographic analysis, samples were extracted three
times with a mixture of hexane and ethyl acetate in the
same proportions. HPLC was performed on a Jasco PU-
2080 Plus system using a RP-18 column (LiChrospher,
5 lm, Merck, Germany) and acetonitrile-water (50:50 v/v)
as mobile phase (0.5 ml/min). Absorbance was monitored
at 254 nm (UV detector, Jasco 870-UV). The column was
eluted in isocratic conditions over 20 min. Data acquisition
and peak areas were determined with the Shimadzu C-R6A
Chromatopac software. The concentration of DEX was
calculated from a calibration curve of known DEX con-
centrations and using triamcinolone as internal standard.
2.2.5 Cytotoxicity evaluation on materials extract
The cytotoxicity evaluation of the SPCL microparticles, was
conducted by the use of MTS (3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetra-
zolium) test, which is extensively used to quantify the
number of viable cells [24, 25]. SPCL microparticles were
sterilized by ethylene oxide (EtO) using pre-optimized
conditions [26]. Each sample was incubated in Dulbecco’s
Modified Eagle’s Medium without phenol red (DMEM,
Sigma, USA) (0.5 mg/ml) supplemented with 10% of heat-
inactivated fetal bovine serum (FBS; Biochrom AG, Ger-
many) and 1% of antibiotic (Gibco, USA), for 24, 48, and
72 h at 37C and 60 rpm, in order to obtain the extract of the
materials containing potential toxic leachables and degra-
dation products. Latex rubber extract and fresh complete
culture medium were used respectively as negative and
positive controls for viability [25]. A Human Osteoblast-like
cell (SaOs-2, ECACC, UK) suspension was plated in 96-well
plates, at density of 6.6 9 104 cell/ml, 0.2 ml/well, and
incubated at 37C in a humidified atmosphere containing 5%
of CO2 for 24 h to allow about 80% of confluence. After this
period, the culture medium was replaced by the material
extract and plates were incubated for further 24 h. The MTS
test was performed according to the CellTiter 96 One Solu-
tion Proliferation Assay Kit (Pormega, USA) manufactures
instructions and as described previously [25]. The absor-
bance was determined in a microplate reader (EL 312e
Biokinetics reader, Biotek Instruments) at 490 nm. The
results are expressed as the percentage (%) of cell viability in
comparison with the 100% proliferation attributed to the
positive control. The samples were tested in five replicates,
and three independent experiments.
2.2.6 Statistical analysis
In order to confirm the difference in the rate of release of
DEX in PBS only and in PBS containing a-amylase and
lipase enzymes, the release data was analysed for statistical
significant differences. The statistical analysis was per-
formed with the OriginPro 7.0 (Microcal software, USA),
fixing the level of significance at P \ 0.05. The normality
of the data was checked by applying the Shapiro–Wilk test
implemented by Origin for this purpose. The statistical
analysis (Student’s t-test for two independent samples) was
used to test the two different data (DEX release in PBS,
and DEX release in enzymatic environment) for the
hypotheses of the release rate in the presence of enzymes to
be significant higher than the release rate in PBS alone.
3 Results
The microcarriers used in this work are shown in Fig. 3a
where microparticles with round shape, porous surface and
diameter of about 400 lm can be observed.
The degradation behaviour of the developed micropar-
ticles was studied by incubating them in different
degradation solutions containing relevant enzymes and
their weight loss was followed over time (Fig. 1). It is well
known that starch is degraded by a-amylase and that PCL
100
100
80
80
60
60
40
40
20
20
0
0
 PBS,  lipase
 
W
ei
gh
t l
os
s (
%
)
Incubation time (days)
α amylase + lipase
α amylase, 
Fig. 1 Weight loss of SPCL microparticles after incubation in
different degradation solutions at 37C. Error bars are standard
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hydrolysis can be catalysed by lipase enzymes [11]. An
increase in weight loss was observed at initial stages of
degradation for all conditions, which then remains constant
for the samples incubated in PBS and a-amylase solution.
In the same figure, significant differences in the percentage
of weight can be observed, depending on the degradation
media. The samples incubated in presence of enzymes
show higher percentages of weight loss, when compared
with the control (PBS), being this effect more notorious for
the degradation solutions containing lipase enzyme. At the
end of the degradation period, the SPCL microparticles lost
approximately 15% of their original weight when incu-
bated in PBS, 45% in presence of a-amylase and 70% in
the presence of lipase. These results clearly indicate a high
degree of degradation of the SPCL microparticles in the
presence of the enzymes.
In order to estimate the degradation of the starch com-
ponent of the blend in the various degradation conditions,
the amount of reducing sugars released in the solutions, as
result of starch hydrolysis, was measured (Fig. 2). The
supernatants where the SPCL microparticles were incu-
bated in the presence of a-amylase showed the highest
concentration of reducing sugars, whereas a negligible
amount of sugars was observed in the control. This result
confirms the susceptibility of the starch present in the blend
to be hydrolysed by a-amylase enzyme at physiological
concentrations. In the presence of lipase, the amount of
detected reducing sugars was very low but a decrease on
the solution pH was observed over time (from pH 7.4 at
day 0 to pH 5.2 at the end of the degradation period). This
drop in the solution pH is due to the release of carboxylic
end groups to the solution as consequence of the ester
hydrolysis in the PCL chain catalyzed by lipase.
The extent of the enzymatic degradation is well illus-
trated in the SEM micrographs shown in Fig. 3. After
degradation in lipase-containing solution, the diameter of
the SPCL microparticles decreased significantly and a
highly porous matrix was obtained.
The chemical changes resulting from the enzymatic
degradation of the particles were detected by FTIR
(Fig. 4). A decrease of the intensity of the band at 1,040–
1,100 cm-1 was detected when samples were incubated
with a-amylase, indicating the action of the enzyme in
cleaving the glycosidic linkages of starch. A reduction on
the intensity of the PCL ester band at 1,700–1,740 cm-1
was observed for the samples incubated with lipase, con-
firming the lipase activity in hydrolyzing ester bonds. The
differences on the bands of starch and PCL demonstrated
the degradation of the two components of the material as a
consequence of the combination of a-amylase and lipase
activities.
The release profile of DEX from SPCL microparticles
for a period of 4 weeks, in PBS and in presence of enzymes
(a-amylase + lipase) is illustrated in Fig. 5. As a general
observation, the release profiles are characterized by two
main stages: the initial burst, mainly during the first day
where more than 20% of the drug was released, and a
sustained release of almost 45% of the DEX at the end of a
4 weeks period. The release profile obtained in an enzy-
matic environment showed a higher amount of the released
DEX into the medium. The statistical analysis of the data
reveals no significant differences between the two release
conditions (PBS and enzymatic environment) for the first
3 h (P values (0.70) [ 0.05). For time periods up to this
time (more than 3 h) and until the end of the release study,
the statistical calculations confirm the hypothesis, at the
0.05 level, the release rate of DEX in the presence of
enzymes is significantly greater than the release in PBS
alone (P values (0.018) \ 0.05). A confidence interval of
95% was fixed for all the calculations.
The MTS results depicted in Fig. 6 showed that 48% of
the cells remained viable when incubated with the extracts
from the SPCL microparticles and the extraction time did
not show any influence on the cytotoxicity results. The
percentage of cell viability may be related with the pres-
ence of residual solvent, used during the preparation of the
microparticles, that might be released to the extract solu-
tion and causing cell death. Additional washing steps will
be included in the microparticle’s preparation to ensure
complete removal of solvents or other toxic reagents.
4 Discussion
Polymeric biomaterials when exposed to body fluids or
placed in contact with tissues, may undergo several
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physicochemical changes as result of the most diverse
interactions with the surrounding environment [1, 2, 11].
The degradation tests performed in this study showed a
higher degradation rate when a-amylase and lipase are
present in the degradation solution. The samples incubated
with lipase enzyme completely lost their spherical shape at
Fig. 3 SEM micrographs of
SPCL microparticles before (a)
and after degradation for
90 days in PBS (b), a-amylase
(c), lipase (d), a-amylase and
lipase (e) solutions
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the end of degradation period. The degradation products in
the presence of a-amylase are mainly sugars resulting from
the cleavage of the glycosidic bonds in the starch structure.
On the other hand, lipase acts in the polyester component
in the blend, at a specific position on the ester bond of the
macromolecule. As result of the degradation process, car-
boxylic acid units are released to the solution, which
explain the observed decrease of the pH. The combination
of the two enzymes resulted in higher values of weight loss
and reducing sugars in solution, indicating the degradation
of both components of the blend.
The SEM analysis confirmed the results discussed
above. The appearance of porosity, cavities and fractures,
and the decrease on the diameter of the SPCL microparti-
cles as result of degradation process, was more notorious in
the presence of lipase and of both enzymes.
There are two main ways for a drug to be released from
a polymeric carrier [27]: (i) diffusion through the polymer,
which depend on the ability of the aqueous environment to
penetrate the drug-containing polymer, inducing the
swelling of the matrix and consequently the release of the
entrapped drug; (ii) degradation of the material containing
the drug, by water, enzymes and acidic or basic conditions.
In this case, the drug starts to be released by diffusion until
a gradual degradation of the polymer takes place thus
controlling the release process. The remaining drug in the
polymeric matrix is released as the degradation process
becomes more significant. For the developed DEX loaded
SPCL microparticles, the initial burst effect was clearly
observed in both studied environments, associated with the
fast release of the drug located close to the surface of the
particles, mainly by the diffusion phenomena. This burst
was followed by a period of minimal release due to the
hydrophobicity of PCL (major component of the blend:
70%), which causes a barrier for water penetration and
consequently preventing the diffusion of the drug through
the polymer matrix. At this stage, the drug was released
faster from the sample in presence of enzymes, indicating
that the enzymatic degradation of the SPCL microparticles
increases the release rate of the entrapped DEX. These
results indicate that the release of DEX from the SPCL
microparticles is firstly controlled by diffusion and then by
the degradation of the polymeric matrix. The dependence
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Fig. 4 FTIR spectra of SPCL microparticles before (a) and after
degradation in presence of a-amylase (b), lipase (c), and a-amylase
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of the drug release with the degradation of the system along
the time makes the SPCL microparticulate system more
adequate for sustained rather than controlled drug release.
The main concern of biodegradable polymers when
proposed for biomedical applications, is the potential tox-
icity of their leachables and degradation products. The
slightly cytotoxicity of the developed system for osteo-
blast-like cells, may be due to the presence of residual
solvent. Previous studies [12] have attributed similar
results to components added and or formed during the
processing.
5 Conclusion
Considering the overall results obtained in this study, it is
expected that the developed SPCL microparticulate system
is a suitable carrier for the sustained release of drugs, with
the advantage of being susceptible to enzymatic degrada-
tion, thus being ultimately digested in the body, avoiding
the surgical removal. These results are indicative of the
potential of the developed system to be used in the con-
trolled release of growth and differentiation factors with
relevance in the field of bone regeneration.
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